ABBV STOCK HITS RECORD ALL TIME HIGH

Discussion in 'AbbVie' started by anonymous, Jun 14, 2017 at 12:17 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    Twitter bro!!
     

  2. anonymous

    anonymous Guest

    ABBV is on the upward move. You heard it here first!
     
  3. anonymous

    anonymous Guest

    Lower highs and lower lows.... looks like breaking bad below $88 is imminent
     
  4. anonymous

    anonymous Guest

    ABBV is still on the rise.
     
  5. anonymous

    anonymous Guest

    Will this be enough to break $100 today? Nope !!!!

    Q2 EPS of $2.00 beats by $0.03.
    Revenue of $8.28B (+19.3% Y/Y) beats by $70M.
     
  6. anonymous

    anonymous Guest


    Surprise Surprise Surprise ER beat Street and Stock tanks almost 4.36% (so far)
    Short this dog. The Longs are Catching the Falling Knife. Lucky i dumped @ $115

    AbbVie Inc
    NYSE: ABBV
    $89.84 USD DOWN−$4.10 (4.36%)
    Jul 27, 9:52 AM
     
  7. anonymous

    anonymous Guest

    Ricky is addressing the Citron attack right now on conference call Also he is discussing the ip system, patent disputes, & settlements. This guy is sweating bullets right now !!!!!!
     
  8. anonymous

    anonymous Guest

    Heres to you Ricky
    ....................../'¯/)
    ....................,/¯../
    .................../..../
    ............./´¯/'...'/´¯¯`·¸
    ........../'/.../..../......./¨¯\
    ........('(...´...´.... ¯~/'...')
    .........\.................'...../
    ..........\............... _.·´
    ............\..............(
    ..............\.............\
     
  9. anonymous

    anonymous Guest

    Rick destroyed Citron. Selling done, shorts done and still tanking. Whose ready for the short squeeze ?
     
  10. anonymous

    anonymous Guest

    The reason stocks tanking after beating ER is because of several reasons
    1. Cintron
    2. FDA
    3. Humira revenue figure was boosted by foreign exchange. Humira's sales increased 8.2% from the prior-year period but y/y growth was subpar compared to historical performance.
    4. HCV/Mavyret' nice looking @ $973 million BUT Mavyret's momentum is slowing and market share decreasing.
    5. Rova T
    6. Ricks an IDIOT
     
  11. anonymous

    anonymous Guest

    and CEO succession pipeline questionable.
     
  12. anonymous

    anonymous Guest

    run to the hills...the analyst say this isnt over until we hit around 55. It was fun while it lasted.
     
  13. anonymous

    anonymous Guest

    Who exactly are the candidates in the CEO succession pipeline?
     
  14. anonymous

    anonymous Guest

    Humira sales down in Q2 with Mylan and Amgen ready to pounce on market share.
    Fast track approval for Rova T turns into no approval.

    Citron attaches a price target of $60.
    Fda fast tracking generics to breech Humira patent proctection.
    Metrics on whole pipeline tanking.
    ROA for 2017 at lowest levels since 2014, returning 7.5% compared to a high of 9.7% in 2015. Working capital for 2017 saw its lowest level of 1.28. Now ROA for 2018 is looking even worse.

    ALL this and Rick raises guidance?
     
  15. anonymous

    anonymous Guest

    agree.... trumpdydumpty isn't doing ABBV any favors.....


    looks like path of least resistance is down
     
  16. anonymous

    anonymous Guest

    Not to mention that good people are leaving the company in droves now that they have their five years in...
     
  17. anonymous

    anonymous Guest

    Since January the stock has fallen a whopping 28%. YIKES !!!
     
  18. anonymous

    anonymous Guest

    I am resigned to the fact that our company's leadership won't be resigning all at once. So, given that fact and the fact that that the pipeline never fails to disappoint, what needs to happen for this company to succeed in a 3-5 year post-Humira timeframe? It seems to me that we need to begin cutting costs now, lay off a lot of people, and shrink this company quickly to what we think will be its post-Humira size. What do you think? What AbbVie leaders can take us where we need to go?
     
  19. anonymous

    anonymous Guest

    The stock price continues to maintain, slowly growing. It's all good!
     
  20. anonymous

    anonymous Guest

    You have obviously never worked anywhere but Abbott so have no idea how this works...